Versant Capital Management’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $102K | Buy |
1,363
+810
| +146% | +$52K | 0.01% | 916 |
|
|
2026
Q1 | $31.2K | Buy |
553
+49
| +10% | +$3.19K | ﹤0.01% | 1545 |
|
|
2025
Q4 | $40.4K | Sell |
504
-325
| -39% | -$21.8K | 0.01% | 1201 |
|
|
2025
Q3 | $40.4K | Buy |
829
+567
| +216% | +$35.1K | 0.01% | 1149 |
|
|
2025
Q2 | $19.5K | Buy |
262
+235
| +870% | +$15.6K | ﹤0.01% | 1553 |
|
|
2025
Q1 | $1.72K | Sell |
27
-2
| -7% | -$136 | ﹤0.01% | 2286 |
|
|
2024
Q4 | $2.26K | Buy |
29
+22
| +314% | +$1.77K | ﹤0.01% | 2034 |
|
|
2024
Q3 | $563 | Hold |
7
| – | – | ﹤0.01% | 1848 |
|
|
2024
Q2 | $579 | Hold |
7
| – | – | ﹤0.01% | 1772 |
|
|
2024
Q1 | $597 | Hold |
7
| – | – | ﹤0.01% | 1656 |
|
|
2023
Q4 | $599 | Hold |
7
| – | – | ﹤0.01% | 1636 |
|
|
2023
Q3 | $627 | Sell |
7
-5
| -42% | -$446 | ﹤0.01% | 1653 |
|
|
2023
Q2 | $1.02K | Buy |
12
+3
| +33% | +$254 | ﹤0.01% | 1594 |
|
|
2023
Q1 | $745 | Hold |
9
| – | – | ﹤0.01% | 1512 |
|
|
2022
Q4 | $708 | Hold |
9
| – | – | ﹤0.01% | 1378 |
|
|
2022
Q3 | $1K | Hold |
9
| – | – | ﹤0.01% | 1239 |
|
|
2022
Q2 | $1K | Hold |
9
| – | – | ﹤0.01% | 1260 |
|
|
2022
Q1 | $1K | Hold |
9
| – | – | ﹤0.01% | 1281 |
|
|
2021
Q4 | $0 | Hold |
9
| – | – | ﹤0.01% | 1504 |
|
|
2021
Q3 | $1K | Hold |
9
| – | – | ﹤0.01% | 1272 |
|
|
2021
Q2 | $1K | Hold |
9
| – | – | ﹤0.01% | 1279 |
|
|
2021
Q1 | $1K | Hold |
9
| – | – | ﹤0.01% | 1363 |
|
|
2020
Q4 | $1K | Hold |
9
| – | – | ﹤0.01% | 1215 |
|
|
2020
Q3 | $0 | Hold |
9
| – | – | ﹤0.01% | 1381 |
|
|
2020
Q2 | $0 | Sell |
9
-11
| -55% | -$1.11K | ﹤0.01% | 1397 |
|
|
2020
Q1 | $1K | Hold |
20
| – | – | ﹤0.01% | 1143 |
|
|
2019
Q4 | $2K | Hold |
20
| – | – | ﹤0.01% | 1137 |
|
|
2019
Q3 | $2K | Sell |
20
-9
| -31% | -$1.14K | ﹤0.01% | 1163 |
|
|
2019
Q2 | $3K | Sell |
29
-120
| -81% | -$11.8K | ﹤0.01% | 1097 |
|
|
2019
Q1 | $13K | Sell |
149
-232
| -61% | -$21.1K | 0.01% | 804 |
|
|
2018
Q4 | $38K | Sell |
381
-10
| -3% | -$1.05K | 0.02% | 314 |
|
|
2018
Q3 | $44K | Sell |
391
-42
| -10% | -$4.35K | 0.02% | 321 |
|
|
2018
Q2 | $38K | Sell |
433
-22
| -5% | -$1.86K | 0.02% | 381 |
|
|
2018
Q1 | $33K | Sell |
455
-6
| -1% | -$412 | 0.01% | 430 |
|
|
2017
Q4 | $26K | Buy |
461
+139
| +43% | +$7.32K | 0.01% | 536 |
|
|
2017
Q3 | $14K | Buy |
322
+11
| +4% | +$457 | 0.01% | 714 |
|
|
2017
Q2 | $12K | Buy |
311
+83
| +36% | +$3.41K | 0.01% | 791 |
|
|
2017
Q1 | $9K | Sell |
228
-7
| -3% | -$273 | 0.01% | 874 |
|
|
2016
Q4 | $9K | Sell |
235
-82
| -26% | -$3.09K | 0.01% | 860 |
|
|
2016
Q3 | $11K | Buy |
317
+151
| +91% | +$5.18K | 0.01% | 775 |
|
|
2016
Q2 | $4K | Sell |
166
-101
| -38% | -$3.05K | ﹤0.01% | 1014 |
|
|
2016
Q1 | $9K | Sell |
267
-11
| -4% | -$355 | 0.01% | 788 |
|
|
2015
Q4 | $8K | Buy |
+278
| New | +$9.02K | 0.01% | 796 |
|
Other funds holding HAE
AI
Versant Capital Management's HAE Position: Q2 2026 in Review
Versant Capital Management increased its Haemonetics (HAE) stake by 146% in Q2 2026, buying an estimated $52K and bringing the position to 1,363 shares worth $102K. The position accounts for 0.01% of the portfolio, ranked #916.
Versant Capital Management first reported a position in HAE in Q4 2015 and has held it in 43 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Versant Capital Management held 1,363 shares of Haemonetics worth $102K as of Q2 2026.
- Versant Capital Management bought 810 Haemonetics shares in Q2 2026, an estimated $52K.
- Haemonetics made up 0.01% of Versant Capital Management's portfolio in Q2 2026, its #916 holding.
- Versant Capital Management first reported a position in Haemonetics in Q4 2015 and has held it in 43 quarters since.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.